Drug Trial Radar · NCT06315205
Evaluation of the Pharmacokinetics, Safety, and Tolerability of IM Letrozole LEBE in Healthy Post-menopausal Women
Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Jul 26, 2023
Primary completion
Mar 11, 2026
Study completion Mar 11, 2026
Sponsor
- Lead sponsor
- Rovi Pharmaceuticals LaboratoriesIndustry
- Sponsor type
- Industry
- First posted
- Mar 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase I, open label, sequential, single ascending dose (SAD) study to evaluate the pharmacokinetic (PK), safety, and tolerability of Letrozole LEBE in healthy post-menopausal women.
Conditions
- Healthy
Interventions
Letrozole LEBE 75 mgDrug
14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 75 mg
Letrozole LEBE 150 mgDrug
14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 150 mg
Letrozole LEBE 225 mgDrug
14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 225mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- λzTime frame: Following single IM administration of Letrozole LEBE (Treatment Period 2, Day 1) until Day 197
- CmaxTime frame: Following single IM administration of Letrozole LEBE (Treatment Period 2, Day 1) until Day 197
- ClastTime frame: Following single IM administration of Letrozole LEBE (Treatment Period 2, Day 1) until Day 197
- tmaxTime frame: Following single IM administration of Letrozole LEBE (Treatment Period 2, Day 1) until Day 197
- tlagTime frame: Following single IM administration of Letrozole LEBE (Treatment Period 2, Day 1) until Day 197
- t1/2Time frame: Following single IM administration of Letrozole LEBE (Treatment Period 2, Day 1) until Day 197
- AUC∞Time frame: Following single IM administration of Letrozole LEBE (Treatment Period 2, Day 1) until Day 197
- AUClastTime frame: Following single IM administration of Letrozole LEBE (Treatment Period 2, Day 1) until Day 197
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Investigational Site number CZ-01
Prague, Czechia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.